Trasis
Charlotte Pilard currently serves as a QA Corporate Officer at Trasis since August 2022. Prior to this role, Charlotte completed a PhD in Biomedical and Pharmaceutical Sciences at Université de Liège, focusing on RANKL blockade and its effects on triple negative breast cancer. Charlotte’s research experience includes internships in oncology research at Université de Franche-Comté, where investigations involved the role of PPAR in carcinogenesis and the action of chemical inhibitors in bladder cancer. A background in laboratory techniques was developed through various internships and trainee positions in laboratory settings, including experiences in anatomo-pathology and biological analyses. Educational qualifications include a Certificat d'université in Quality Assurance from the University of Liège, a Master's Degree in Cellular and Molecular Signaling, and a Bachelor's Degree in Biochemistry and Biology.
Trasis
At Trasis our primary focus is allowing the medical community to access new radiolabelled therapeutic and diagnostic substances easier and faster. To this end, we design, manufacture, sell and support high performance synthesizers, dose preparation equipment, their shielding and accessories. We also develop customized synthetic methods and instruments. We can provide GMP Active Pharmaceutical Ingredients (API) and assist our customers with their regulatory affairs. Our proven radiopharmaceutical expertise, coupled with our high end instruments allow us to provide fully integrated solutions for an effective tracer production and faster transition from drug development to marketing authorization. Our equipment is used worldwide in nuclear medicine departments, research centers, radiopharmaceutical production facilities and pharmaceutical companies.